167690-53-1

Basic information

• Product Name: FMOC-TRANEXAMIC ACID
• Synonyms: FMOC-TRANS-4-(AMINOMETHYL)CYCLOHEXANE-1-CARBOXYLIC ACID;FMOC-TRANS-4-(AMINOMETHYL)-CYCLOHEXANECARBOXYLIC ACID;FMOC-TRANEXAMIC ACID;N-FMOC-TRANEXAMIC ACID;TRANS-4-[(9H-FLUOREN-9-YLMETHOXYCARBONYLAMINO)-METHYL]-CYCLOHEXANECARBOXYLIC ACID;TRANS-4-(FMOC-AMINOMETHYL)CYCLOHEXANECARBOXYLIC ACID;Tran-4-(Fmoc-aminomethyl)cyclohexanecarboxylic acid;Fmoc-trans-4-Amc-OH
• CAS NO: 167690-53-1
• Molecular Formula: C₂₃H₂₅NO₄
• Molecular Weight: 379.45
• Product Categories: Miscellaneous Amino Acids;Amino Acids
• Mol File: 167690-53-1.mol
• Article Data: 5

Chemical Properties

• Melting Point: 188 °C
• Boiling Point: 604.9 °C at 760 mmHg
• Flash Point: 319.6 °C
• Appearance: /
• Density: 1.226 g/cm³
• Storage Temp.: 2-8°C
• PKA: 4.85±0.10(Predicted)
• CAS DataBase Reference: FMOC-TRANEXAMIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-TRANEXAMIC ACID(167690-53-1)
• EPA Substance Registry System: FMOC-TRANEXAMIC ACID(167690-53-1)

Safety Data

• WGK Germany: 3
• F: 10
• HazardClass: IRRITANT
• Hazardous Substances Data: 167690-53-1(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Upstream product

• 1197-18-8 trans-4-aminomethyl-cyclohexyl-carboxylic acid 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 

Downstream Products

• 1702967-37-0 (3S,10S,14S)-3-[(naphthalen-2-yl)methyl]-1,4,12-trioxo-1-[(1r,4S)-4-({2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetamido}methyl)cyclohexyl]-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid 
• 114681-67-3 N-(Nicotinoyl)-trans-4-aminomethylcyclohexanecarboxylic acid 

Relevant articles and documents

Beyond Basicity: Discovery of Nonbasic DENV-2 Protease Inhibitors with Potent Activity in Cell Culture

The viral serine protease NS2B-NS3 is one of the promising targets for drug discovery against dengue virus and other flaviviruses. The molecular recognition preferences of the protease favor basic, positively charged moieties as substrates and inhibitors, which leads to pharmacokinetic liabilities and off-target interactions with host proteases such as thrombin. We here present the results of efforts that were aimed specifically at the discovery and development of noncharged, small-molecular inhibitors of the flaviviral proteases. A key factor in the discovery of these compounds was a cellular reporter gene assay for the dengue protease, the DENV2proHeLa system. Extensive structure-activity relationship explorations resulted in novel benzamide derivatives with submicromolar activities in viral replication assays (EC50 0.24 μM), selectivity against off-target proteases, and negligible cytotoxicity. This structural class has increased drug-likeness compared to most of the previously published active-site-directed flaviviral protease inhibitors and includes promising candidates for further preclinical development.

Synthesis, biological evaluation, and docking studies of PAR2-AP-derived pseudopeptides as inhibitors of kallikrein 5 and 6

A series of protease activated receptor 2 activating peptide (PAR2-AP) derivatives (1-15) were designed and synthesized. The obtained compounds were tested on a panel of human kallikreins (hKLK1, hKLK2, hKLK5, hKLK6, and hKLK7) and were found completely i

Large-scale syntheses of FMOC-protected non-proteogenic amino acids: Useful building blocks for combinatorial libraries

Convenient and reliable large-scale procedures for the protection of various amino acids with N-(9-fluorenylmethoxycarbonyl)oxysuccinimide (FMOC-OSu) are described. Commercially available 4-aminomethylbenzoic acid and trans-4-(aminomethyl)cyclohexanecarbo